Literature DB >> 31407053

Commentary on: "Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12".

Francesca De Felice1, Daniela Musio2, Vincenzo Tombolini2, Enrico Cortesi3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31407053     DOI： 10.1007/s00384-019-03364-5

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN： 0179-1958            Impact factor:   2.571


× No keyword cloud information.
  3 in total

1.  Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.

Authors:  Emmanouil Fokas; Michael Allgäuer; Bülent Polat; Gunther Klautke; Gerhard G Grabenbauer; Rainer Fietkau; Thomas Kuhnt; Ludger Staib; Thomas Brunner; Anca-Ligia Grosu; Wolff Schmiegel; Lutz Jacobasch; Jürgen Weitz; Gunnar Folprecht; Anke Schlenska-Lange; Michael Flentje; Christoph-Thomas Germer; Robert Grützmann; Matthias Schwarzbach; Vittorio Paolucci; Wolf O Bechstein; Tim Friede; Michael Ghadimi; Ralf-Dieter Hofheinz; Claus Rödel
Journal:  J Clin Oncol       Date:  2019-05-31       Impact factor: 44.544

2.  Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer.

Authors:  Francesca De Felice; Ilaria Benevento; Anna Lisa Magnante; Daniela Musio; Nadia Bulzonetti; Rossella Caiazzo; Vincenzo Tombolini
Journal:  BMC Cancer       Date:  2017-05-12       Impact factor: 4.430

Review 3.  Adaptive design methods in clinical trials - a review.

Authors:  Shein-Chung Chow; Mark Chang
Journal:  Orphanet J Rare Dis       Date:  2008-05-02       Impact factor: 4.123
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.